Quantitative Correlation Between the Time Course of Plasma Pyridostigmine Levels and Neuromuscular Function in Myasthenia Gravis a

Although anticholinesterase drugs are generally the first line of treatment of myasthenia gravis (MG), there is still no objective way to determine optimal dosage. Recent studies using analytical methods have provided data on the pharmacokinetics of pyridostigmine. However, the relationship between plasma levels of pyridostigmine and the time course of the therapeutic effect has not been objectively determined. The aim of the present study was to examine this relationship by measuring plasma pyridostigmine levels concurrently with five clinicophysiological parameters of neuromuscular function.